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ABSTRACT 
 
Rationale for the study 
The growth of pharmaceutical expenditure as a percentage of total health care expenditure has 
stagnated, both locally and globally, despite increasing consumption. Two factors that 
contributed to the stagnation are the introduction of generic medicines after patent expiry, and 
the introduction of cost-containment policies, like generic reference pricing. The introduction of 
generic medicines offer the opportunity to reduce medicine expenditure because of a switch in 
utilisation from expensive brand-name originator products to more cost-effective generic 
alternatives. Reference pricing is a policy where therapeutically similar medicines are grouped 
together, and a maximum reimbursement rate is set for the group. If a patient chooses to use a 
product more expensive than the reference price, they have to pay the difference in price. In the 
South African context, generically similar products are grouped together and the reimbursement 
rate is set at the average price of the generically equivalent products. 
 
Aims and objectives 
The aim of the study is to determine the impact of the introduction of generics and generic 
reference pricing on two active ingredients, candesartan and rosuvastatin, which recently lost 
their patent protection, in the South African private health care sector, for the period January 
2012 to December 2015. To achieve this aim, three objectives were identified: 
1. To measure the impact on medicine utilisation after the introduction of generics and 
generic reference pricing on candesartan and rosuvastatin. 
2. To measure the impact on the average medicine price after the introduction of generics 
and generic reference pricing on candesartan and rosuvastatin. 
3. To measure the impact on medicine expenditure after the introduction of generics and 
generic reference pricing on candesartan and rosuvastatin. 
 
Method 
Medicine claims for candesartan and rosuvastatin was obtained from a Pharmacy Benefit 
Manager in South Africa. The claims covered a 48-month period from January 2012 to 
December 2015 and provided a pre- and post-reference price period for analysis. Medicine 
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utilisation was measured as the number of Defined Daily Doses dispensed per 100 000 
beneficiaries. Medicine price and expenditure was calculated as the average per Defined Daily 
Dose. 
 
Results 
Candesartan experienced an average 7.0% year-on-year decline in utilisation and rosuvastatin a 
5.0% increase. Utilisation of generic medicines was 59.3% of the total volume in the final year 
of the study for candesartan and 76.4% for rosuvastatin. The introduction of generic alternatives 
resulted in a 31.0% reduction in the average price per Defined Daily Dose for candesartan and a 
13.9% reduction for rosuvastatin. Medicine expenditure reduced by an additional 34.6% and 
20.9% for candesartan and rosuvastatin respectively, because of the introduction of generic 
reference pricing. The total saving because of the introduction of generics and generic reference 
pricing was 54.8% for candesartan and 31.9% for rosuvastatin. 
 
Conclusion 
The introduction of generics and generic reference pricing did not have an impact on overall 
medicine utilisation, but reduced the price and expenditure of both candesartan and rosuvastatin. 
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CHAPTER 1 
 
1. INTRODUCTION 
 
Pharmaceutical expenditure is still increasing internationally, although growth has slowed down 
since the mid-2000's [1, 2]. According to a recent Organisation for Economic Co-operation and 
Development (OECD) report, Health at a glance 2015, pharmaceutical expenditure has reached 
$80 billion in OECD countries in 2013 [1]. QuintilesIMS predicts that worldwide 
pharmaceutical sales will be 30% higher in 2018 than it was in 2013 [2]. This growth will 
mostly be because of growth in the United States (US) market and in developing countries, like 
South Africa, while growth in the top 5 countries in the European market (Germany, United 
Kingdom (UK), France, Italy and Spain) is predicted to be between one and four percent in the 
same period [2]. In South Africa, pharmaceutical expenditure in the private sector reached ZAR 
22.3 billion in 2015, a 36.8% increase from the ZAR 16.3 billion spent in 2012 [3].  
 
The introduction of new medicines and the increasing demand for existing medicines are the 
main drivers of pharmaceutical spending. The quantity of medicines consumed has increased 
over time in many therapeutic classes. Most notably, between 2000 and 2013, the use of 
antihypertensive medication in OECD countries nearly doubled, while the use of cholesterol 
lowering drugs tripled [1]. In South Africa, a similar trend of increasing consumption can be 
seen, with hypertension prevalence increasing from 114.6 per 1 000 beneficiaries in 2011 to 
152.8 per 1 000 beneficiaries in 2015 [3]. 
 
Despite the nominal growth in pharmaceutical expenditure and the increased consumption, 
pharmaceutical expenditure as a percentage of total health expenditure has reached a plateau [1, 
2]. Pharmaceutical expenditure was responsible for between 17% and 20% of total health 
expenditure in OECD countries in 2013 [1]. The 3.2% drop in pharmaceutical expenditure in 
the five year period since 2009 is in sharp contrast to the average 2.7% growth each year in the 
preceding five years. Prior to 2005 spending on retail pharmaceuticals grew at a faster rate than 
other health care sectors and was a major contributor in driving overall health care expenditure 
[1]. In South Africa, pharmaceutical expenditure contributed 16.1% to overall health 
expenditure in the private sector in 2015, only marginally more than the 15.8% in 2012 [3].  
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Two factors that contributed to the stagnation in growth of pharmaceutical expenditure is the 
introduction of generic medicines and the introduction and strengthening of cost-containment 
policies [1, 4]. According to the World Health Organization (WHO), a generic medicine is 
defined as "a pharmaceutical product, usually intended to be interchangeable with an innovator 
product, that is manufactured without a license from the innovator company and marketed after 
the expiry date of the patent or other exclusive rights" [5]. Generic medicines offer the 
opportunity to make substantial savings without affecting the quality of care [6]. In the US 
market, the price of generic medicines are 80% to 85% lower than the brand name product [1]. 
The introduction of generic medicines sees dramatically lower volume utilisation of the more 
expensive brand name products, which results in savings in pharmaceutical expenditure [2]. In 
the top 5 markets in Europe the introduction of generic medicines has had an impact of more 
than $16 billion every year since 2006 [2]. In South Africa, generic medicines are 22 % cheaper 
than their brand name equivalents, and 56% cheaper than products without any generic 
competition [5]. Generic medicines were responsible for 56.2% of all medicines dispensed in 
South Africa in 2015 [5]. 
 
Although the introduction of generic medicines played an important role in containing medicine 
expenditure in the last decade, there are other cost containment strategies used world-wide that 
also contributed to the stagnation in growth [4]. One of the cost-containment policies used to 
promote the use of generic medicines is reference pricing. In essence, reference pricing groups 
therapeutically similar medicines together and sets a maximum reimbursement rate for the 
group of medicines [7]. Any medication with a price below the reference price will be covered, 
i.e paid,  in full, while medicine with a higher price will only be partially reimbursed with the 
beneficiary paying the balance between the price of the chosen medicine and the reference 
price. Reference pricing is not a price control. It has an indirect impact on medicine expenditure 
through medicine use changes [7]. Reference pricing can change the demand for expensive 
brand name medicines, when people elect to use cheaper generic alternatives to avoid out-of-
pocket co-payments. Three levels of reference pricing exist [7]. In level one, medicines that 
have identical bioactive ingredients and are considered therapeutically interchangeable, are 
grouped together. This is also referred to as generic reference pricing.  This type of reference 
pricing has been implemented in Canada (Ontario), Denmark, Italy, Norway, Sweden and the 
USA [7]. Level two reference pricing groups medicines in analogue groups. The medicines are 
chemically slightly different, but have comparable or identical indications. This is also referred 
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to as therapeutic reference pricing. Therapeutic reference pricing has been implemented in 
British Columbia, Canada [7]. In level three, all medicines used to treat a condition are grouped 
together. Examples where level three reference pricing has been implemented include 
Netherlands and Germany [7]. Reference pricing at level one has less risk of adverse effects, 
however the potential for savings is also less at level one [7]. In South Africa the first 
applications of generic reference pricing (level one reference pricing) can be found as far back 
as 2005 [8]. Reference pricing does not have adverse effects on health outcomes [7, 9]. It also 
did not increase the use of other health services, with the possible exception of an increase in 
doctors consultations when reference pricing is introduced and patients want to switch to 
cheaper reference medicines [10]. 
 
There are numerous studies analysing the impact of generic medicines on pharmaceutical 
expenditure, as well as the impact of generic reference pricing on pharmaceutical expenditure. 
Data from low and middle income countries, like South Africa, however remain limited. The 
aim of this study was to determine the impact of the introduction of generics and generic 
reference pricing on candesartan and rosuvastatin, utilisation, pricing and expenditure for the 
period January 2012 to December 2015, in an environment where generic reference pricing was 
already applied on other unprotected pharmaceutical products. The impact was measured on 
medicine utilisation, the average medicine price as well as the impact on medicine expenditure. 
This study will help answer the question whether reference pricing has longer term benefits after 
the initial introduction of the reference pricing policy, which usually results in a reduction in 
medicine expenditure.  
 
To answer the research question, medicine claims for candesartan and rosuvastatin from a 
Pharmacy Benefit Manager (PBM) in South Africa was analysed using a retrospective 
longitudinal research design. A longitudinal study is one that takes place over time, with two or 
more waves of measurement [11]. A longitudinal database of all the claims that met the 
inclusion criteria was constructed. A longitudinal database is a searchable mass of computerised 
data providing information about individuals over time [12]. A list of all the fields and 
descriptions of the database can be found in Appendix 1. The database includes demographic 
information about the beneficiaries, including date of birth, age and gender. For confidentiality, 
all beneficiary identification numbers were decoded and de-identified. Authorisation was 
obtained from the PBM to use the claims data for the study (Appendix 2). To ensure the 
reliability and validity of the results, a list of quality criteria suggested by Ramsay et al. (1980) 
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was adopted when the research methods and tools were designed [13]. The list of the quality 
criteria and their application can be found in Appendix 3. 
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CHAPTER 2  
 
2. LITERATURE REVIEW 
 
2.1 Generic medicine 
 
2.1.1 Definition and application 
There are many definitions used for generic medicines around the world. The WHO defines 
generic medicine as: 
 " a pharmaceutical product which: is usually intended to be interchangeable with an 
 innovator product, is manufactured without a licence from the innovator company, and 
 is marketed after the expiry of the patent or other exclusive rights" [5]. 
The US Food and Drug Administration (FDA) defines generic medicine as: 
 "a drug product that is comparable to brand/reference listed drug product in dosage 
 form, strength, route of administration, quality and performance characteristics, and 
 intended use" [14]. 
Finally, the European Medicines Agency (EMA), which oversees EU-wide authorisation of 
medicines, defines a generic medicine as:  
 "a medicine that is developed to be the same as a medicine that has already been 
 authorised (the 'reference medicine'). A generic medicine contains the same active 
 substance(s) as the reference medicine, and it is used at the same dose(s) to treat the 
 same disease(s) as the reference medicine. However, the name of the medicine, its 
 appearance (such as colour or shape) and its packaging can be different from those of 
 the reference medicine" [14].  
Despite the numerous definitions used world-wide, generic medicines are generally understood 
to be medicines not protected by a patent, which is bioequivalent to a medicinal product already 
authorised, with the same qualitative and quantitative composition of active ingredients, the 
same pharmaceutical form, and the same therapeutic indications [15]. If these conditions are 
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met, generics are considered to have an equivalent clinical effect when substituted for the 
original brand-name product [16].  
 
One of the main principals used to ensure comparable safety and efficacy between original 
products and their generic equivalents, is bioequivalence [14]. Bioequivalence has been defined 
as follows: 
 "two pharmaceutical products are bioequivalent if they are pharmaceutically 
 equivalent and their bioavailabilities (rate and extent of availability) after 
 administration in the same molar dose are similar to such a degree that their effects , 
 with respect to both efficacy and safety, can be expected to be essentially the same. 
 Pharmaceutical equivalence implies the same amount of the same active  substance(s), 
 in the same dosage form, for the same route of administration, and meeting the same or 
 comparable standards" [14]. 
The bioequivalence standards for generic medicines used internationally is very similar. Both 
the US FDA and the EMA require that generic medicines demonstrate a bioavailability of 0.80 - 
1.25 compared to the originator drug [14, 17]. There are however differences between countries 
for the standards of Narrow Therapeutic Index (NTI) medicines. In the US the same standard of 
0.80 - 1.25 is used for NTI medicines, while in Europe the bioavailability for NTI medicines has 
a tightened acceptance level of 0.90 - 1.11 [14]. In Australia there are no generic versions of 
digoxin or phenytoin, and the two brands of warfarin available in the Australian market are not 
considered interchangeable [14]. In South Africa, the Medicines Control Council (MCC) also 
use the 0.80 - 1.25 bioavailability standard, but provision is made to use a non-South African 
product as the reference standard [17]. A study of 135 generic products available in South 
Africa, could not find any differences between originator brands, branded generics or unbranded 
generics [18]. The tolerance levels allowed for bioavailability for generic medicines have been 
favourably compared to those acceptable for inter-batch variation during production of the 
originator medicine [14]. Because of the bioequivalence standards, most countries world-wide 
allow an abbreviated registration process for generic medicines, where pre-clinical and clinical 
studies do not have to be performed by the generic medicine manufacturer [14].  
 
Generic substitution is a policy that allow the dispenser of medicine to substitute a brand-name 
product with a cheaper generic alternative [16]. Depending on the jurisdiction, this substitution 
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can be performed with or without consulting the prescriber of the medicine [19]. 
Implementation of a generic substitution policy has been found to stimulate generic use and 
reduce pharmaceutical expenditure [19]. 
 
2.1.2 Safety and efficacy 
The major argument opponents of generic medicines and generic substitution has, is the issue 
surrounding the safety and efficacy of generic medicines. Specifically, how does the safety and 
efficacy of generic medicines compare to their originator counterparts. Several studies have 
been published on the subject. Kesselheim et al. (2008) published an extensive systematic 
review and meta-analysis on the clinical equivalence between generic and brand-name 
medicines used in the treatment of cardiovascular disease [20]. The 47 studies in their sample 
included 8 subclasses of cardiovascular medicines, including two types of NTI medicines. The 
clinical outcomes that were measured included: clinical laboratory values such as International 
Normalised Ratio (INR) and urine electrolytes; adverse effects or other morbidity; and health 
care system utilization, including clinic and emergency department visits. They concluded that 
generic and brand-name cardiovascular medicines are similar in nearly all clinical outcomes 
[20]. Data extrapolated from two large randomised controlled trials (RCTs) published in the 
early 2000's, Controlled-ONset Verapamil Investigation of Cardiovascular Endpoints 
(CONVINCE) and Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack 
(ALLTHAT), also found that there was no difference in clinical outcomes between brand-name 
originator medicines and their generic equivalents, but that other factors such as race and 
adherence to therapy are more likely to influence clinical outcomes [21].   
 
While the active pharmaceutical ingredient is the same in originator brand-name products and 
their generic equivalents, there might be a difference in excipients used in the products. A 
number of excipients are known to have side-effects or contra-indications [14]. Gothe (2015), 
also argues that decreased quality of excipients and manufacturing quality can impact the 
release and intended action of the active ingredient in generic medicines, but found no 
difference in clinical outcomes between originator medicines and their generic counterparts 
[16]. 
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There are, however, still some controversy regarding generic substitution in specific therapeutic 
medicine categories, specifically anti-epileptic drugs (AEDs). Significant problems have been 
reported, including breakthrough seizures and increased side effects following a switch to a 
generic AED [14]. Dunne (2013) concluded that, at least in the case of AEDs, bioequivalence, 
as defined in regulations, does not always correspond to therapeutic equivalence because of the 
permitted range, evaluation methods and individual variation [14]. A systematic review and 
meta-analysis on seizure outcomes following generic substitution by Kesselheim et al. (2010), 
refutes this claim and found that the available evidence does not suggest an association between 
loss of seizure control and generic substitution in at least three types of AEDs [22].  
 
2.1.3 Medicine utilisation 
Utilisation of generic medicines has been increasing in Europe and the US in the last decade [1, 
2]. In Europe, generic medicines were responsible for almost half of the volume of medicines 
dispensed in 2009 [23]. In 2013, this number increased to almost 76% [1]. There is, however, 
significant variations in generic utilisation between countries in Europe. European countries 
with higher generic utilisation rates included the UK and Germany (65% of volume in 2009) 
[24, 23], and the Netherlands (more than 50% of volume in 2007) [19]. European countries at 
the lower end of the generic utilisation spectrum include France (40% of volume) [23], Spain 
(30% of volume) [23] and Italy (28% of expenditure) [15]. In the US, generic medicines 
represent about 70% to 80% of the total medicine volume [23, 25]. Data for countries outside 
Europe and the US is much more limited. Latin American countries have a generic utilisation 
rate comparable with the US and Europe [23], while in China generic medicines only represent 
approximately 34% of the total volume of medicines dispensed [26]. In South Africa, in 2015, 
generic medicines were responsible for 56% of the volume of medicines dispensed, and 41% of 
medicine expenditure [5]. 
 
Market structures (including number of off-patent medicines) and prescribing practices are 
responsible for some of the differences in generic uptake between the countries, but generic 
utilisation can also be stimulated through pharmaceutical policies [1]. In the Netherlands, for 
example, the potential cost savings because of the use of generic medicines was recognised 
early, and policies such as generic substitution was implemented and expanded to stimulate 
growth [19]. Apart from generic substitution, countries can also make use of International Non-
proprietary Name (INN) prescribing practices, financial incentives to physicians and 
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pharmacists, reduced co-payments for (or zero co-payments) on generic medicines, and 
reference pricing to stimulate growth in the generic medicines market [1]. 
 
2.1.4 Medicine Price 
In most jurisdictions around the world, generic medicines qualify for an abbreviated application 
process where no pre-clinical and clinical studies are required, but bioequivalence to the 
originator medicine must be demonstrated. The abbreviated registration process is one of the 
main reasons for the price difference between generic and originator medicines [14].  
 
The magnitude of the variation in price between generics and originator medicine differs 
between countries around the world. Just in Europe, the difference is generally between 20% to 
80%, depending on the country [26]. In Spain there is almost no difference between the price of 
the generic medicine and their originator product [27], in Italy it is between 40% and 60% [15], 
and up to 90% for some products in the UK and the Netherlands [27]. In South Africa, in a 
sample of 346 medicines used in the treatment of cardiovascular disease, 75% of the generic 
medicines were more than 40% cheaper than their branded version [28]. 
 
Generic competition, in general, changes the market and decreases the price of medicines [26]. 
Some countries are however more successful in managing to reduce the price of generic 
medicines. This can be achieved through local price regulations, reimbursement arrangements, 
demand-side pressures (e.g. education), and reference pricing [14].  
 
2.1.5 Medicine expenditure 
Due to their lower price and comparable safety and efficacy, an increase in generic medicine 
utilisation will result in a decrease in medicine expenditure [26]. In the US, in 2010 alone, the 
use of generic medicines saved the American health system US$158 billion, or an average of 
US$3 billion every week [14]. A study by Sheingold (2014), found that the shift toward less 
expensive generic medicines had cut in half the rate of increase in the price of a prescription on 
Medicare Part D in the US. A further saving of 60% of total Part D spending was possible if a 
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100% generic dispensing rate for eligible products was achieved [25]. Zeng (2013), found a 
saving of more than 60% in costs because of generic substitutions in China [26]. 
 
An unintended consequence of generic substitution is an increase in adherence. This could be 
due to reduced out-of-pocket expenses for patients, which have been associated with increased 
medication adherence [21, 15, 29]. The increase in adherence could lead to savings in other 
health care segments, e.g. preventing avoidable hospitalisations [21]. 
 
Although switching from originator medicines to their generic counterparts could save money in 
principle, in practice it is often more complex and dependant on a host of other factors [23]. 
Gothe (2015), argues that because of a higher rate of adverse events associated with generic 
substitution in certain therapeutic groups, overall health care expenses may exceed the amount 
saved by the lower acquisition costs of generic medicines [16]. It must however be noted that 
the study focussed only on sensitive therapeutic categories which included NTI medicines, and 
was in part funded by a manufacturer of originator medication. There are however, other ways 
to increase generic utilisation, as outlined in the next section.   
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2.2 Reference pricing 
 
2.2.1 Definition and application 
The term reference pricing might be confusing in the economic sense, because the name implies 
that it is a pricing policy, whereas in reality, reference pricing is a reimbursement policy [30]. 
Under reference pricing, medicines that are deemed to be therapeutically equivalent or 
interchangeable are grouped together (referred to as a reference group), and a maximum 
reimbursement rate is set for the group of medicines [14, 31]. The reimbursement rate for a 
specific group can be the price of the lowest cost product in the reference group, or it can be 
based on an average price of all the products in the group [31]. If a medicine at a higher price 
does not buy greater effectiveness or reduced toxicity, then 3rd party insurers in resource 
constrained settings should not cover the extra costs [30]. If a patient elects to use a product 
more expensive than the reference price, they will pay the difference in price between the 
elected product and the reference price [14, 32]. Reference pricing has widespread international 
application, beginning in Germany in 1989, followed by the Netherlands and New Zealand 
shortly thereafter, and more than a dozen countries since [33]. 
 
According to Aaserud (2007) reference pricing can be applied to different levels of reference 
groups. In level one, medicines that have identical bioactive ingredients and are considered 
therapeutically interchangeable are grouped together. This is also referred to as generic 
reference pricing.  This type of reference pricing has been implemented in Canada (Ontario), 
Denmark, Italy, Norway, Sweden and the USA [7]. Level two reference pricing groups 
medicines in analogue groups. The medicines are chemically slightly different, but have 
comparable or identical indications. This is also referred to as therapeutic reference pricing. 
Therapeutic reference pricing has been implemented in British Columbia, Canada [7]. In level 
three, all medicines used to treat a condition are grouped together. Examples where level three 
reference pricing has been implemented include Netherlands and Germany [7]. Reference 
pricing at level 1 has less risk of causing adverse effects, but the potential for savings is also 
much less because the reference group is restricted to brand and generic versions of the same 
active ingredient [7]. 
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Reference pricing is not a price control, because retail prices are not set. It is rather an indirect 
method of price control or a reimbursement pricing system [7]. Manufacturers are free to set a 
price above the reference price, but then the patient has to pay the difference in price. Reference 
pricing has also been called incentive pricing because it provides incentives to direct prescribing 
and providing in favour of less expensive reference medicines [30]. It is designed in such a way 
that financial incentive and initiative are shifted from the provider to the patient, which exposes 
the patient to the financial consequences of their medicine use [32]. 
 
2.2.2 Medicine utilisation 
In general, the introduction of reference pricing causes a shift in utilisation away from more 
expensive cost share medicines, to cheaper reference medicines, without negatively affecting 
overall utilisation of the reference group [7, 33]. A systematic review by Aaserud et al. (2007), 
found that the use of reference medicines increased by 60% to 196% immediately after the 
introduction of the reference price policy, while the use of cost share drugs decreased by 19% to 
42% [7]. The relatively higher increase in the use of reference medicines compared to the 
decrease in cost share medicines, indicates that the utilisation of reference medicines was at a 
much lower base than cost share medicine, before the implementation of the reference price 
policy. Schneeweiss et al. (2007) also found a switch away from cost share medicines towards 
reference medicines after reference pricing was introduced in British Columbia, Canada. The 
results were less dramatic, but still substantial, with a 10% to 50% switching rate to reference 
medicines [30].  
 
The shift from cost share medicines to reference medicines could however, be price sensitive 
[34]. If the incentive for the patient to move to a reference medicine is weak because the price 
difference between the cost share medicine and the reference price is low, the patient is more 
likely to stay on the cost share medicine and pay the difference out-of-pocket [30]. The 
introduction of generic reference pricing in Australia illustrated the effect of the price difference 
on the switching rate between cost share and reference medicines. Fluoxetine had a large price 
difference between the originator medicine and the reference price, whereas ranitidine had a 
much smaller difference. After 12 months, the reference fluoxetine products had a greater 
utilisation rate than the originator product, while for ranitidine the reference products only 
reached 30% of the utilisation rate of the originator cost share product [34]. In British 
Columbia, Canada, the use of reference H2-antagonists increased by 379% after the introduction 
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of therapeutic reference pricing in 1995[35]. It must be noted that the introduction of reference 
pricing coincided with a policy to restrict access to proton pump inhibitors (PPIs) to patients 
who met certain eligibility criteria, which could skew the effect of the reference pricing policy 
on generic utilisation.  
 
Similar to the generic substitution policy, reference pricing has also been associated with an 
increase in medication adherence [33]. McManus et al. (2001), however, found that the 
introduction of reference pricing without a policy of mandatory generic substitution had little 
effect on changing utilisation behaviour [34].  
 
2.2.3 Medicine price 
Reference pricing causes a decline in the price of medicines in the reference group [7]. A 
systematic review by Lee at al. (2012) found that 4 of the 9 reference pricing policies they 
identified resulted in a reduction of medicine prices of the reference group, with a mean 
reduction of 11.5% (range 7% - 24%) [33]. 
 
The magnitude of the price reduction is, however, very variable and depends on the level of 
reference pricing, the therapeutic class of the reference group as well as the jurisdiction in which 
the reference price policy is applied [7, 36]. The introduction of generic reference pricing in 
Sweden in 1993 resulted in an initial decrease in prices for medicines, with an average 19% 
reduction in price for medicines in the reference group [37]. The introduction of generic 
reference pricing by a large medical scheme administrator in South Africa in the early 2000's, 
showed that 66% of the products in the reference group experienced a price decrease in the first 
12 months after the policy was introduced [38]. Although the prices of medicines in the 
reference group declined after the introduction of reference pricing in Germany and the 
Netherlands, prices for products not covered by the reference pricing policy have been reported 
to increase [37].  
 
In general, reference pricing is effective in forcing prices down to the reference price, but 
manufacturers have a clear disincentive to lower prices below the reference price [31, 30]. 
Pavcnik (2005) reported that the originator brand-name products reduce their prices 
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significantly more than their generic counterparts [39]. Prices of generic medicines reduced on 
average by only 11% after the introduction of reference pricing in Germany, whereas the prices 
of branded products decreased on average by 26%. The lower reduction in generic prices is 
likely due to the disincentive to reduce the price below the reference price. 
 
2.2.4 Medicine expenditure 
Reference pricing can reduce medicine expenditure significantly for third party insurers [7]. The 
changes in expenditure can be composed of: a) a shift in utilisation from expensive cost share 
medicines to cheaper reference medicines; b) beneficiaries paying a larger part of the 
expenditure; and c) reduced prices. 
 
Similar to the reduction in price, the reduction in third party expenditure also varies by 
therapeutic class [40, 35, 30]. Savings are largest when the highest priced product in the 
reference group is also the most utilised, and when the reference price is determined per unit 
dispensed and not per day of treatment [30]. The level of reference price applied also has an 
impact on the savings that can be achieved. Grootendorst et al. (2005) reported that reference 
pricing at level 1 (generic reference pricing) produced only one quarter of the savings of 
reference pricing at level 2 (therapeutic reference pricing) [36].  
 
Depending on the benefit design, reference pricing can also lead to decreased co-payments for 
beneficiaries if there is no co-payment charged on reference medicines below the reference 
price [33]. 
 
2.2.5 Health and health care utilisation 
Since reference pricing policies might affect medicine utilisation, they could also have an effect 
on health and other non-pharmaceutical health care utilisation [7]. However, no adverse effects 
on health have been associated with a reference pricing policy [30]. With regards to health care 
utilisation, three studies reported a slight increase of between 7% - 11%, in physician visits 
shortly after the introduction of the reference pricing policy [40, 7, 33]. The increase in 
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physician visits was most likely due to patients visiting their doctors to change from a cost share 
to a reference medicine. 
 
2.3 Background to the South African pharmaceutical environment 
 
South Africa is an upper middle income country and like most low and middle income countries 
there is pressure on resources because of growing demand, especially for health care services 
[41]. South Africa has a two-tiered health system with 8.8 million people (16% of the 
population), insured by private insurers, while the remainder of the country is dependent on the 
public health system [3, 42]. This study only focused on a subset of the 8.8 million people 
covered by private insurance.  
 
After the first democratic election in 1994 a national drug policy (NDP) was developed in 1996 
to "develop a pricing plan for drugs used in South Africa in the public and private sectors" [43]. 
Several legislative changes were required to South Africa's medicines law, the Medicines and 
Related Substances Control Act (Act 101 of 1965), to implement the changes proposed in the 
NDP [44]. Some of these changes included banning "sampling" and "bonusing" of medicines 
and the establishment of a pricing committee [45]. The aim of these changes were to create a 
transparent pricing system which would include a single exit price (SEP) for medicines. The 
SEP legislation which came into effect in 2003, created a single price at which pharmacists and 
other authorised health care professionals were allowed to sell medicines to the public in the 
private health care market. The SEP was initially defined as the weighted average of the 
medicine price in 2003 and thereafter an annual maximum price increase was published by the 
minister of health [45]. In addition to the SEP imposed on manufacturers, legislation was also 
introduced in 2004 to cap the professional fee pharmacies were allowed to charge for the 
dispensing of medicines [45]. Mandatory offer of generic substitution also became legal in 
2003, which allowed pharmacists to substitute brand name products with a generic equivalent, 
without requiring approval from the prescriber of the medicine [45]. The legalisation of generic 
substitution paved the way for the introduction of generic reference pricing in the private health 
care sector in South Africa. The first applications of generic reference pricing in the South 
African health care market can be found as far back as 2005 [8, 38]. There is very little research 
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as to the impact of these policies on medicine use, price and expenditure in South Africa, and 
this study will hope to fill the existing evidence gap. 
 
2.4 Pharmacology 
 
2.4.1 Candesartan 
Candesartan is an antihypertensive medicine which belongs to the therapeutic class of 
angiotensin II receptor blocking agents (ARB) [46]. The ARBs are a relatively new class of 
antihypertensive agents [47]. Unlike angiotensin converting enzyme (ACE) inhibitors, the 
ARBs has no effect on bradykinin metabolism and are therefore more selective blockers of 
angiotensin effects [46]. ARBs available in South Africa include candesartan, eprosartan, 
irbesartan, losartan, telmisartan and valsartan [48].  
 
Mechanism of action 
Angiotensin II causes direct vasoconstriction as well as stimulating the release of aldosterone, 
which causes the reabsorption of both water and sodium, resulting in an elevation of blood 
pressure [47]. Unlike ACE inhibitors, the ARBs do not affect the renin-angiotensin system [47]. 
Candesartan inhibits the effect of angiotensin II on its receptor, angiotensin type 1 (AT1), 
thereby directly blocking angiotensin II-induced arteriolar vasoconstriction [46] [48]. This 
mechanism of action offers a more complete angiotensin II inhibition by interacting selectively 
with the receptor site [48].  
 
Pharmacokinetic profile 
Candesartan cilexitil is an ester prodrug that is converted to candesartan during absorption from 
the gastrointestinal tract [48]. Candesartan cilexetil is rapidly and completely bioactivated by 
ester hydrolosis to the active ingredient candesartan. It is mainly excreted unchanged in the 
urine (33%) and faeces (67%). Absolute bioavailability is estimated to be 15% and half-life 
elimination is approximately 9 hours [47]. 
 
        Chapter2 - Literature review 
 
    
17 
 
Indications 
Candesartan is used for the treatment of essential hypertension, especially where left ventricular 
hypertrophy is present [48]. In cardiac failure, candesartan can be used in combination with 
ACE inhibitors, or as an alternative to ACE inhibitors [48]. ARBs are also used in the treatment 
of myocardial infarction and diabetic nephropathy [47].  
 
Dosage 
The adult dose for hypertension is 8mg once daily, which may be increased after 4 weeks to a 
maximum of 32mg once daily. The usual maintenance dose is 8-16mg once daily. For cardiac 
failure the initial dose is 4mg once daily, and can be increased at intervals of at least 2 weeks to 
a maximum of 32mg once daily [48].  
 
Safety 
Candesartan should be used with caution in pregnancy and in patients who previously 
experienced angio-oedema with an ACE inhibitor [48].   
 
The side effects of ARBs are similar to those of the ACE inhibitors, with the exception of cough 
and angio-oedema, which are possibly mediated by bradykinin [46]. Common adverse effects 
include headache, dizziness, syncope, muscle weakness, hypotension, rash, inflammation, 
urticaria, pruritus, alopecia, dry skin, diarrhoea, abdominal pain, nausea, constipation, dry 
mouth, dental pain, and sinus disorders [47]. Common drug interactions include non-steroidal 
anti-inflammatory drugs (NSAIDs) (cause an increase in blood pressure and swelling), 
potassium supplements (increased potassium levels in the blood) and lithium [47].   
 
2.4.2 Rosuvastatin 
Rosuvastatin is a competitive inhibitor of HMG-CoA(3-hydroxy-3-methylglutaryl-coenzyme A) 
reductase. This therapeutic class of medicines is also known as statins or reductase inhibitors  
[46] [48]. These compounds are structural analogues of HMG-CoA [46]. The main therapeutic 
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effect of statins is the reduction of artherogenic lipoprotein levels as a result of the inhibition of 
HMG-CoA in the liver. The reductin of artherogenic lipoproteins also have other benefits 
including enhanced stability of atherosclerotic lesions, and improved function of vascular 
endothelial cells [49]. Statins available in South Africa include atorvastatin, fluvastatin, 
lovastatin, pravastatin, rosuvastatin, and  simvastatin [48].  
 
Mechanism of action 
HMG-CoA reductase mediates the first committed step in sterol biosynthesis. Statins induce an 
increase in low-density lipoprotein (LDL) receptors, which causes an increase in the fractional 
catabolic rate of LDL in the liver, as well as an increase in the liver's extraction of LDL 
precursors. This results in a reduction in the plasma pool of LDL [46]. At maximal doses, the 
reduction of LDL cholesterol can be up to 60%. Variable increases in HDL and modest 
decreases in triglyceride levels have also been noted after treatment with statins [46] [48]. 
 
Pharmacokinetic profile 
Rosuvastatin has a high first pass extraction by the liver, but this is not entirely undesirable 
because the liver is the primary site of action of the statins [48]. The dose response curve for 
rosuvastatin is approximately linear [49]. Most of the absorbed dose is excreted in the bile and 
about 5-20% is excreted in the urine [46]. Rosuvastatin has poor bioavailability (20%) due to its 
extensive first-pass metabolism. Elimination half-life is approximately 19 hours, about 10% is 
metabolised and 90% eliminated unchanged in the faeces [48]. Food intake decreases the rate of 
absorption of rosuvastatin, but not the extent of absorption [50].  
 
Indications 
HMG-CoA inhibitors can be used alone or in combination with bile acid-binding resins in the 
treatment of severe hypercholesterolaemia, hign-risk moderate  hypercholsterolaemia, and may 
also be effective in some cases of mixed hyperlipidaemia [48].  
 
Dosage 
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To obtain a 25-30% reduction in LDL cholesterol, approximately 2.5mg of rosuvastatin is 
required. A doubling of the dose will provide another 6% reduction. Initially, an oral dosage of 
5mg once daily, adjusted after 2 weeks if necessary with a range of 10-40mg once daily [48]. 
Most of the synthesis of cholesterol occurs at night, and therefore the shorter acting statins 
should also be given at night. Since Rosuvastatin is a longer acting statin, it can be taken at any 
time [48].  
 
Safety 
Rosuvastatin is contraindicated in hepatic disease or in patients with elevated serum 
transaminases [48]. Rosuvastatin should be used with caution in women who are pregnant or 
who are likely to become pregnant. Use in children is restricted to those with heterozygous 
familial hypercholesterolaemia [46].  
 
Common adverse effects include abdominal pain, constipation, diarrhoea and flatulence, nausea, 
dyspepsia, headache, insomnia, sleep disturbances, skin rash, peripheral neuropathy, memory 
loss, sexual dusfunction, depression, angio-oedema, hypotension and interstitial lung disease. 
Rhabdomyolysis with renal failure has occured and the incidence and severity of myopathy are 
increased by drug interactions. Common drug interactions include ciclosporin, fluconazole, 
itraconazole, gemfibrozil, lopinavir, ritonavir (all cause increased rosuvastatin levels) and 
antacids (concommitant use results in reduced serum rosuvastatin levels) [48]. 
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CHAPTER 3 
 
3. PAPER 1  
 
Preface 
This article has been submitted to the "International Journal of Clinical Pharmacy". The 
manuscript below was formatted according to author guidelines for this journal. Proof of 
submission of this manuscript to International Journal of Clinical Pharmacy, comprising of e-
mail acknowledging receipt of submission, screenshot of first page of approved PDF, can be 
found in Appendix 4. 
 
Ethical Clearance documents can be found in Appendix 5. 
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Running Title 
The impact of the introduction of generics and generic reference pricing on candesartan 
and rosuvastatin utilisation, price and expenditure in South Africa 
Abstract 
Background: In the South African private sector context, generically similar products are 
grouped together and the reimbursement rate is set at the average price of the generically 
equivalent products. Very little evidence exists in low and middle-income countries with 
regards to the impact of this policy over time. 
Objectives: To determine the impact of the introduction of generics and generic reference 
pricing on candesartan and rosuvastatin in the South African private health care sector in terms 
of medicine utilisation, medicine price and medicine expenditure. 
Setting: South African private health sector 
Method: Medicine claims for candesartan and rosuvastatin was obtained from a Pharmacy 
Benefit Manager in South Africa. The claims covered a 48-month period from January 2012 to 
December 2015 and provided a pre- and post-reference price period for analysis. Medicine 
utilisation was measured as the number of Defined Daily Doses dispensed per 100 000 
beneficiaries. Medicine price and expenditure was calculated as the average per Defined Daily 
Dose. 
Main outcome measure: Medicine utilisation, price and expenditure 
Results: Candesartan experienced an average 7.0% year-on-year decline in utilisation and 
rosuvastatin a 5.0% increase. Medicine expenditure reduced by an additional 34.6% and 20.9% 
for candesartan and rosuvastatin respectivel. The total savings was 54.8% for candesartan and 
31.9% for rosuvastatin. 
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Conclusion: The introduction of generics and generic reference pricing did not have an impact 
on medicine utilisation, but reduced the price and expenditure of both candesartan and 
rosuvastatin. 
Key words 
Generics, Generic reference pricing, Medicine expenditure, South Africa 
Impact of research findings on pharmacy/clinical practice 
 Generic substitution and generic reference pricing could reduce medicine expenditure 
without affecting health outcomes 
 Utilisation of generic medicines, after patent expiry, improves over time as more 
competitors enter the market 
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Introduction 
Pharmaceutical expenditure is still increasing internationally, although growth has slowed down 
since the mid-2000s [1, 2]. In South Africa, pharmaceutical expenditure in the private sector 
reached ZAR 22.3 billion in 2015, a 36.8% increase from the ZAR 16.3 billion spent in 2012 
[3]. The introduction of new medicines and the increasing demand for existing medicines are 
the main drivers of pharmaceutical spending [2]. The quantity of medicines consumed has 
increased over time in many therapeutic classes. Most notably, between 2000 and 2013, the use 
of antihypertensive medication in Organization for Economic Co-operation and Development 
(OECD) countries nearly doubled, while the use of cholesterol lowering drugs tripled [1]. In 
South Africa, a similar trend of increasing consumption can be seen, with hypertension 
prevalence increasing from 114.6 per 1,000 beneficiaries in 2011 to 152.8 per 1,000 
beneficiaries in 2015 [3]. Despite the nominal growth in pharmaceutical expenditure and the 
increased consumption, pharmaceutical expenditure as a percentage of total health expenditure 
has reached a plateau [1, 2]. In South Africa, pharmaceutical expenditure contributed 16.1% to 
overall health expenditure in the private sector in 2015, only marginally more than the 15.8% 
spent in 2012 [3]. 
Two factors that contributed to the stagnation in growth of pharmaceutical expenditure is the 
introduction of generic medicines and the introduction and strengthening of cost-containment 
policies [1, 4]. Generic medicines offer the opportunity to make substantial savings without 
affecting the quality of care [5]. The introduction of generic medicines may lower utilisation of 
more expensive brand name products, which results in savings in pharmaceutical expenditure 
[2]. In South Africa, generic medicines are on average 22% cheaper than their brand name 
equivalents, and 56% cheaper than products without any generic competition [6]. Generic 
medicines were responsible for 56.2% of all drugs dispensed in South Africa in 2015 [6]. One 
of the cost-containment policies used to promote the use of generic medicines is reference 
pricing. In essence, reference pricing groups therapeutically similar medicines together and sets 
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a maximum reimbursement rate for the group of medicines [7]. Any medication with a price 
below or at the reference price will be covered in full, while medicine with a higher price will 
only be partially reimbursed with the beneficiary paying the balance between the price of the 
chosen medicine and the reference price. Reference pricing can change the demand for 
expensive brand name medicines, when people elect to use cheaper generic alternatives to avoid 
out-of-pocket co-payments. Reference pricing does not have adverse effects on health outcomes 
[7, 8]. It also does not increase the use of other health services, with the possible exception of an 
increase in doctors’ consultations when reference pricing is introduced and patients want to 
switch to cheaper reference medicines [9]. 
Background to the South African pharmaceutical environment 
South Africa is a developing country with limited health care resources [10]. The country has a 
two-tiered health care system with 8.8 million people (16% of the population) insured by private 
insurers [3, 11]. A national drug policy (NDP) was established in 1996 which led to the 
establishment of a pricing committee and the introduction of a Single Exit Price (SEP) on all 
pharmaceuticals in the private health sector [12, 13]. Mandatory offer of generic substitution 
was introduced in 2003 which empowered pharmacists to offer to substitute brand name 
products with a generic equivalent [14]. These changes paved the way for the introduction of 
generic reference pricing in the private health sector, with the first applications as far back as 
2005 [15] 
Aim of the study 
There are numerous studies analysing the impact of generic medicines on pharmaceutical 
expenditure, as well as the impact of generic reference pricing on pharmaceutical expenditure. 
Data from low and middle income countries, like South Africa, however, remain limited. The 
aim of this study is to determine the impact of the introduction generics and generic reference 
pricing on candesartan and rosuvastatin, who recently lost their patent protection, in an 
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environment where generic reference pricing is already applied on other unprotected 
pharmaceutical products. The impact was measured on medicine utilisation, the average 
medicine price as well as the impact on medicine expenditure. This study will help answer the 
question regarding whether reference pricing has longer term benefits after the initial 
introduction of the reference pricing policy, which usually results in a reduction in medicine 
expenditure. 
Ethical approval 
Ethical approval for this study was granted by the University of KwaZulu-Natal (UKZN) 
Biomedical Research Ethics Committee (BREC), reference number BE348/15. 
Method 
This study is a retrospective longitudinal analysis of a medicine claims database. Medicine 
claims data was supplied by an independent Pharmacy Benefit Manager (PBM) in South Africa. 
For the study period, the PBM processed medicine claims for 1.45 million private health care 
beneficiaries in South Africa. The database includes demographic information about the 
beneficiaries, including: date of birth, age, and gender. All beneficiary identification numbers 
were decoded and de-identified to ensure confidentiality. To ensure the reliability and validity 
of the results, a list of quality criteria for interrupted time series designs was adopted when the 
research methods and tools were designed [16]. 
The study period covered a 48-month period from January 2012 to December 2015. Both 
rosuvastatin and candesartan received generic competition in this period and generic reference 
pricing was subsequently introduced on the active ingredients. Generic reference pricing was 
introduced in April 2013 for rosuvastatin, and in February 2014 for candesartan. For both 
rosuvastatin and candesartan, the study period provided a pre-intervention base where generic 
reference pricing was not applied, to determine the impact of generic reference pricing after 
generic alternatives became available. 
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Only beneficiaries from registered medical schemes who were contracted with the PBM for the 
entire study period were included in the study population. This was done to control 
inconsistencies in the before and after comparisons of the introduction of generic reference 
pricing, because of changes in volume and the make-up of the study population. Of the medical 
schemes contracted with the PBM for the entire study period, only those who applied generic 
reference pricing were included in the study population. Medical schemes that had major benefit 
design changes in the study period, e.g. changes in medicine formulary or other co-payment 
changes, were excluded from the study. These changes in benefit design could have an impact 
on the utilisation and expenditure of rosuvastatin and candesartan, not because of the 
introduction of generics and generic reference pricing. 
Changes in medicine utilisation was measured by converting the claimed quantity to Defined 
Daily Dose (DDD) per 100 000 beneficiaries. DDD represents the assumed mean maintenance 
dose per day for a medicine when used for its main indication [17]. The standardisation of 
medicine volume to DDD enables utilisation comparisons across the different strengths of the 
same active ingredient. To control changes in the study population, the medicine volume was 
calculated as DDD dispensed per 100 000 beneficiaries, on the basis of the membership data of 
the medical schemes included in the study population. 
All medicine prices were obtained from the South African Medicine Price Registry, Database of 
Medicine Prices [18]. Prices are expressed in South African Rand (ZAR) and were adjusted to 
the year in which generic reference pricing was first introduced on the active ingredient. The 
Single Exit Price Adjustment (SEPA) published in the South African Government Gazette was 
used to adjust the prices according to the year in which the product was dispensed [6]. Prices for 
candesartan are expressed in ZAR 2014 (Q2) and rosuvastatin in ZAR 2013 (Q1). Prices 
excludes dispensing fee and sales tax (value added tax (VAT) in South Africa). Price was 
calculated by multiplying the volume sold with the adjusted SEP and dividing by the number of 
DDD dispensed. Price therefore always refers to the price per DDD of the active ingredient. 
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Medicine expenditure was calculated by multiplying the medicine price with the volume utilised 
and subtracting the patient out-of-pocket co-payments because of the application of generic 
reference pricing. 
Results 
The characteristics of the 1 444 beneficiaries using candesartan, and the 10 452 beneficiaries 
using rosuvastatin were stable during the 48-month study period. For candesartan, 765 
beneficiaries had claims in both the pre- and post-reference price periods, and for rosuvastatin 4 
738 beneficiaries claimed in both periods. Women represented 46% of the beneficiaries for the 
candesartan group and 43% of the rosuvastatin group. The mean age was 65.0 (standard 
deviation 12.3 years) and 61.2 years (standard deviation 11.5 years) for the candesartan and 
rosuvastatin groups respectively. 
Medicine Utilisation 
Candesartan experienced a 19.6% reduction in DDD dispensed per 100 000 beneficiaries over 
the study period, or an average 7.0% year-on-year change over the four years. Rosuvastatin 
experienced a 15.6% increase in DDD dispensed per 100 000 beneficiaries over the study 
period, or an average 5.0% year-on-year over the four years. As illustrated in Figure 1, the 
change in the number of DDD dispensed per 100 000 beneficiaries was a gradual change over 
time for both candesartan and rosuvastatin and was not caused by a big shift because of the 
introduction of generics and generic reference pricing. 
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Figure 1 Candesartan and rosuvastatin utilisation for the period January 2012 to 
December 2015 
 
 
Although the overall number of DDD dispensed per 100 000 beneficiaries was not affected by 
the introduction of generics and generic reference pricing, there was a significant change in the 
mix of original brand name products versus generic alternatives dispensed after the introduction 
of generics and generic reference pricing. The initial uptake of generic equivalents in the year of 
the introduction of generic reference pricing was significant, and increased even further in 
subsequent years. For candesartan, the generic utilisation reached 47.4% in the year of the 
introduction of generic reference pricing, and grew further to 59.3% in the following year. 
Generic utilisation of rosuvastatin started at 24.0% in the year of the introduction of generic 
reference pricing, and increased to 63.9% in the subsequent year and 76.4% in the year 
thereafter. Figure 2 illustrates the change in the mix of original brand name products and generic 
equivalents over the study period. 
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Figure 2 Candesartan utilisation of original brand name product and generic alternatives, 
measured in DDD per 100 000 beneficiaries 
 
Figure 3 Rosuvastatin utilisation of original brand name product and generic alternatives, 
measured in DDD per 100 000 beneficiaries 
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Medicine Price 
Average price reductions range from 13.9% to 31.0% for rosuvastatin and candesartan 
respectively. The average price per DDD for candesartan reduced from ZAR 4.28 to ZAR 2.96, 
while the average price per DDD for rosuvastatin decreased from ZAR 8.06 to ZAR 6.94 in the 
study period. The magnitude of the difference in price between the original brand name product 
compared to the average price of the generic equivalents was much greater for candesartan 
compared to rosuvastatin. For candesartan, the average generic equivalent product is 54.5% 
cheaper than the original brand name product, while the difference in price for rosuvastatin was 
only 24.9%. 
Table 1 Candesartan and rosuvastatin price (in ZAR) and expenditure (in ZAR) per DDD 
 Candesartan Rosuvastatin 
 Pre RP
1
 Post RP
2
 Saving Pre RP
3
  Post 
RP
4
 
Saving 
Average Price per DDD 4.28 2.96 31.0% 8.06 6.94 13.9% 
Original Brand Price per DDD 4.32 4.20 2.8% 8.08 8.20 -1.6% 
Average Generic Price per 
DDD 
N/A
5
 1.91 N/A
5
 N/A
5
 6.16 N/A
5
 
Average Expenditure per DDD 4.28 1.93 54.8% 8.06 5.49 31.9% 
            
Price Saving per DDD   1.33 31.0%   1.12 13.9% 
Reference Price Saving per 
DDD 
  1.02 34.6%   1.45 20.9% 
Total Saving per DDD   2.35 54.8%   2.57 31.9% 
 
1
The pre-reference price period for candesartan was from January 2012 to January 2014 
2
 The post-reference price period for candesartan was from February 2012 to December 2015 
3
 The pre-reference price period for rosuvastatin was from January 2012 to March 2013 
4
 The post-reference price period for rosuvastatin was from April 2013 to December 2015 
5
There were no generic equivalent products available in the pre-reference price period. As a result, the 
average price per DDD and saving could not be calculated 
Medicine expenditure 
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The introduction of generic reference pricing produced an additional saving on medicine 
expenditure of 34.6% for candesartan and 20.9% for rosuvastatin. This saving is in addition to 
the 31.0% and 13.9% saving that resulted from the reduction in price per DDD because of the 
introduction of generic equivalents. Candesartan expenditure decreased from ZAR 4.28 to ZAR 
1.93 per DDD after the intervention. Rosuvastatin expenditure decreased from ZAR 8.06 to 
ZAR 5.49 per DDD. The application of generic reference pricing resulted in a reference price 
co-payment of ZAR 1.02 per DDD for candesartan and ZAR 1.45 per DDD for rosuvastatin. 
Figure 3 illustrates the additional impact of generic reference pricing on medicine expenditure 
after the introduction of the reference price in February 2014 for candesartan, and April 2013 
for rosuvastatin. 
The total saving in medicine expenditure per DDD is 54.8% for candesartan and 31.9% for 
rosuvastatin. This equates to a saving of ZAR 1.4 million for candesartan and ZAR 8.8 million 
for rosuvastatin during the post-reference price period in the study. 
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Figure 4 Candesartan and rosuvastatin price and expenditure per DDD for the period 
January 2012 to December 2015 
 
1
 Generic reference pricing for candesartan was introduced in February 2014 
2
 Generic reference pricing for rosuvastatin was introduced in April 2013 
3
 In the period March 2013 to December 2013 there was only one generic equivalent product available 
for rosuvastatin, distributed by the same manufacturer as the original brand name product 
 
Discussion 
Hypertension and hyperlipidaemia remain two of the most prevalent non-communicable 
diseases in the South African health care landscape. According to the 2015 Mediscor Medicines 
Review (MMR), antihypertensives was the top therapeutic group according to medicine 
expenditure, while the hypolipidaemic agents were ranked sixth [6]. In 2012, a year prior to the 
introduction of generics and generic reference pricing, the various strengths of brand name 
rosuvastatin occupied two places in the list of top 20 products according to expenditure (6th and 
12th).  
The introduction of generics and generic reference pricing did not change the overall utilisation 
of either candesartan or rosuvastatin. It did however have an impact on the mix of original brand 
name products and generic equivalents that were claimed in the post-reference price period. The 
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higher generic uptake for rosuvastatin can be ascribed to a longer post-reference price period, 
greater number of generic competitors during this period, and the introduction of a clone 
product by the manufacturer of the original brand name product. The high initial generic uptake 
of both candesartan and rosuvastatin is because of the practice of both generic substitution 
(since 2003) and generic reference pricing on other classes of pharmaceutical products. 
The greater number of generics and generic uptake for rosuvastatin did not result in greater 
savings in price per DDD in the post-reference price period. The price per DDD for rosuvastatin 
decreased by 13.9%, while candesartan experienced a 31.0% reduction. The greater savings in 
price per DDD for candesartan is a result of a greater price difference between the original 
brand name product and the average price of generic equivalents. For candesartan, the average 
price of the generic equivalent products was 54.5% cheaper than the brand name product, while 
for rosuvastatin the difference was only 24.9%. The price difference for rosuvastatin is however 
somewhat diluted, because for the first six months after the introduction of reference pricing 
there was only one generic equivalent product available, distributed by the same manufacturer 
as the original brand name product at a 19.7% discount. In the following 24 months, an 
additional three competitor generic equivalent products were launched, and the premium on the 
brand name product increased to 27.0% compared to the average generic price. The difference 
between the price of the original brand name product and the generic equivalents is not as big as 
seen in other countries in the world [1, 2, 9]. This could possibly be because of a smaller 
number of generic competitors in the South African market as well as the price controls 
enforced through the SEP legislation. 
The reduction in the average price per DDD is solely contributed to the introduction of generic 
alternatives. Although it is possible that reference pricing had an influence on the decision of 
beneficiaries to move to a generic alternative, this study cannot correlate the change directly to 
reference pricing because beneficiaries did not have the opportunity to choose a generic 
alternative before the introduction of reference pricing. The introduction of reference pricing 
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did, however, result in reductions in the expenditure per DDD because of the out-of-pocket co-
payments experienced by members who elected to use a product above the reference price. It 
can be argued that this additional saving is only a saving to the insurer and not a saving to 
overall health care expenditure, because beneficiaries will be responsible for out-of-pocket co-
payments. Further research is required as to how many beneficiaries opted for the additional 
out-of-pocket expenditure and why. Candesartan experienced an additional 34.6% saving on the 
expenditure per DDD because of the introduction of reference pricing, resulting in an overall 
saving of 54.8% per DDD. Rosuvastatin had an additional saving of 20.9% in expenditure per 
DDD, resulting in an overall saving of 31.9%.  
Conclusion 
Generic reference pricing offers the ability to generate additional savings in pharmaceutical 
expenditure in the longer term, as more original brand name products lose their patent 
protection and generic alternatives are introduced in the market. This study only focussed on the 
private health care market in South Africa, and the impact on the public health sector still needs 
to be determined. Further studies are needed on more products as well as the impact on the 
entire therapeutic class to ensure that beneficiaries aren't switching to other products not 
affected by reference pricing. 
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CHAPTER 4 
 
4. SUMMARISED RECOMMENDATIONS AND CONCLUSION 
 
4.1 Recommendations 
The introduction of generic medicines, generic substitution and reference pricing are effective 
policies to shift medicine utilisation away from expensive originator medicine to more cost 
effective generic reference medicines. South Africa, in an effort to create a transparent pricing 
system and reduce the cost of medicine, might have legislated some of the medicine expenditure 
savings, out of these policies. The utilisation of generic medicines in South Africa compares 
favourably with utilisation rates of some countries in Europe, but we are still lagging behind the 
leading countries like the US, UK and Germany. Unfortunately, because of the relatively high 
price of our generic medicines, we are not realising the same medicine expenditure savings as 
other countries. 
 
The introduction of level 1 generic reference pricing in South Africa has had a positive impact 
on medicine expenditure. If the reference groups are expanded to level two, where medicines in 
the same therapeutic class are referenced together, even greater savings can be achieved. The 
risk of adverse events in level two reference pricing is greater when switching medicines 
(compared to level 1 reference pricing), but by avoiding high risk therapeutic groups like 
antiepileptic drugs, this risk can be managed and greater savings can be achieved. 
 
The implementation of a reference pricing policy seems to have longer term benefits, than just 
the initial reduction in price after implementation of the policy. As demonstrated by candesartan 
and rosuvastatin in South Africa, reference pricing could also lead to future medicine 
expenditure savings as more originator medicines lose their patent protection and generic 
medicines are introduced to the market. With the current international trend of increasing 
medicine consumption due to an ageing population, these policies will play a critical role in 
ensuring that medicines remain affordable and accessible to all.  
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4.2 Conclusion 
This study revealed that the introduction of generics and generic reference pricing is effective in 
changing utilisation towards lower cost generic equivalent medicines. For candesartan and 
rosuvastatin in South Africa, the change in generic utilisation rate caused a reduction in both the 
price of medicine, as well as the pharmaceutical expenditure by third party payers. Although the 
results are positive, the magnitude of the savings can be improved by further lowering the price 
of generic equivalent products to rates that are comparable to international reference prices and 
by expanding the reference groups to level 2 therapeutic groups. To be able to generalise the 
results of this study to all medicines in South Africa, the impact analysis will have to be 
expanded to include all medicines within the therapeutic class as well as expand the selection to 
more therapeutic classes. 
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APPENDIX 1  
Table 2 Longitudinal database fields and descriptions 
 
Field description 
Decoded claims identification number 
Claim submit date 
Date of service 
Provider number 
Provider name 
Provider discipline (speciality) 
Decoded member identification number 
Gender 
Date of birth 
Product identification code 
Product name 
Generic indicator 
Manufacturer code 
Manufacturer name 
Claim quantity 
SEP unit price 
Reference price 
Scheme amount due 
Reference price co-payment 
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APPENDIX 2 
PBM permission letter 
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APPENDIX 3 
Table 3 Quality criteria for ITS designs 
 
Criteria Application 
Intervention occurred independently of other 
changes over time 
Third party payers who introduced any other 
benefit design changes on rosuvastatin and 
candesartan were excluded from the study 
Intervention was unlikely to affect data 
collection 
Data was collected retrospectively, after the 
introduction of reference pricing 
The primary outcome was assessed blindly or 
was measured objectively 
All four of the study outcomes (medicine cost, 
medicine volume, medicine expenditure and 
out-of-pocket payments) can be measured 
objectively for both the pre-and-post 
intervention measures 
The primary outcome was reliable or was 
measured objectively 
Outcome measurement is objective, change in 
slope of linear regression line 
The composition of the data set at each point 
covered at least 80% of the total number of 
participants in the study 
All participants who qualify for the study 
according to the inclusion criteria will be 
included in the longitudinal database covering 
the 48 months of the study 
The shape of the intervention effect was pre-
specified 
A change in the slope of the linear regression 
line is expected 
The study was analysed appropriately using 
time series techniques 
Time series regression models will be used to 
analyze the data 
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APPENDIX 6 
Table 4 Candesartan descriptive statistics of study population 
 
Statistic Pre RP Post RP Total 
Total claim lines 14063 11794 25857 
No of unique 
beneficiaries 
1113 960 1444 
No of beneficiaries 
that claimed in pre 
and post RP periods 
  765 
Ben average age 64.58 65.43 64.97 
Ben median age 65.02 65.60 65.33 
Ben mode age 71.83 56.15 66.38 
Age variance 147.73 152.57 150.11 
Age std dev 12.15 12.35 12.25 
Female 0.46 0.46 0.46 
Male 0.54 0.54 0.54 
Age 19-29 0.001484 0.001014 0.00127 
Age 30-39 0.022337 0.018165 0.020436 
Age 40-49 0.081925 0.071765 0.079552 
Age 50-59 0.249947 0.238256 0.244621 
Age 60-69 0.277161 0.288189 0.282185 
Age 70-79 0.255248 0.241298 0.248894 
Age 80-89 0.102283 0.122677 0.111573 
Age 90-99 0.009613 0.013687 0.011469 
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APPENDIX 7 
Table 5 Rosuvastatin descriptive statistics of study population 
 
Statistic Pre RP Post RP Total 
Total claim lines 53124 138907 192031 
No of unique 
beneficiaries 
5930 9261 10452 
No of beneficiaries 
that claimed in pre 
and post RP periods 
  4738 
Ben average age 60.46 61.49 61.20 
Ben median age 60.61 61.61 61.34 
Ben mode age 61.45 61.99 61.99 
Age variance 131.19 133.54 133.10 
Age std dev 11.45 11.56 11.54 
Female 0.43 0.43 0.43 
Male 0.57 0.57 0.57 
Age 19-29 0.008301 0.007055 0.0074 
Age 30-39 0.024659 0.0229 0.023387 
Age 40-49 0.131937 0.116682 0.120902 
Age 50-59 0.295667 0.28401 0.287235 
Age 60-69 0.317427 0.318364 0.318105 
Age 70-79 0.180465 0.196772 0.192261 
Age 80-89 0.039304 0.050782 0.047607 
Age 90-99 0.00224 0.003434 0.003104 
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APPENDIX 8 
Table 6 Candesartan SEP comparison: January 2012 to December 2015 
 
Month Atacand 16mg 
Mylacand 
16mg 
Candagen 
16mg 
Mediscor 
Reference 
Price 
January 2012 6.69393       
February 2012 6.69393       
March 2012 6.83714       
April 2012 6.83714       
May 2012 6.83714       
June 2012 6.83714       
July 2012 6.83714       
August 2012 6.83714       
September 2012 6.83714       
October 2012 6.83714       
November 2012 6.83714       
December 2012 6.83714       
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Month Atacand 16mg 
Mylacand 
16mg 
Candagen 
16mg 
Mediscor 
Reference 
Price 
January 2013 6.83714       
February 2013 6.83714       
March 2013 7.23357       
April 2013 7.23357       
May 2013 7.23357       
June 2013 7.23357       
July 2013 7.23357       
August 2013 7.23357       
September 2013 7.23357       
October 2013 7.23357 3.03800     
November 2013 7.23357 3.03800     
December 2013 7.23357 3.03800     
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Month Atacand 16mg 
Mylacand 
16mg 
Candagen 
16mg 
Mediscor 
Reference 
Price 
January 2014 7.23357 3.03800     
February 2014 7.23357 3.03800   3.04000 
March 2014 7.23357 3.03800   3.04000 
April 2014 7.23357 3.03800   3.04000 
May 2014 7.23357 3.03800   3.04000 
June 2014 7.23357 3.21467   3.04000 
July 2014 7.23357 3.21467 3.03800 3.22000 
August 2014 7.23357 3.21467 3.03800 3.22000 
September 2014 7.23357 3.21467 3.03800 3.22000 
October 2014 7.23357 3.21467 3.03800 3.22000 
November 2014 7.23357 3.21467 3.03800 3.22000 
December 2014 7.23357 3.21467 3.03800 3.22000 
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Month Atacand 16mg 
Mylacand 
16mg 
Candagen 
16mg 
Mediscor 
Reference 
Price 
January 2015 7.23357 3.21467 3.03800 3.22000 
February 2015 7.23357 3.21467 3.03800 3.22000 
March 2015 7.77607 3.21467 3.03800 3.22000 
April 2015 7.77607 3.45600 3.26600 3.22000 
May 2015 7.77607 3.45600 3.26600 3.46000 
June 2015 7.77607 3.45600 3.26600 3.46000 
July 2015 7.77607 3.45600 3.26600 3.46000 
August 2015 7.77607 3.45600 3.26600 3.46000 
September 2015 7.77607 3.45600 3.26600 3.46000 
October 2015 7.77607 3.45600 3.26600 3.46000 
November 2015 7.77607 3.45600 3.26600 3.46000 
December 2015 7.77607 3.45600 3.26600 3.46000 
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APPENDIX 9 
Table 7 Rosuvastatin SEP comparison: January 2012 to December 2015 
 
Month Crestor 20mg Zuvamor 20mg Vusor 20mg Storwin 20mg Rosvator 20mg 
Mediscor 
Reference Price 
January 2012 8.241670           
February 2012 8.241670           
March 2012 8.418000           
April 2012 8.418000           
May 2012 8.418000           
June 2012 8.418000           
July 2012 8.418000           
August 2012 8.418000           
September 2012 8.418000           
October 2012 8.418000           
November 2012 8.418000           
December 2012 8.418000           
  
          Appendix 9 
 
    
58 
 
Month Crestor 20mg Zuvamor 20mg Vusor 20mg Storwin 20mg Rosvator 20mg 
Mediscor 
Reference Price 
January 2013 8.418000 7.155360         
February 2013 8.418000 7.155360         
March 2013 8.906330 7.155360         
April 2013 8.906330 7.155360       7.160000 
May 2013 8.906330 7.155360       7.160000 
June 2013 8.906330 7.155360       7.160000 
July 2013 8.906330 7.155360       7.160000 
August 2013 8.906330 7.155360       7.160000 
September 2013 8.906330 7.155360 5.343670 5.343670   7.160000 
October 2013 8.906330 7.155360 5.343670 5.343670 7.125000 7.160000 
November 2013 8.906330 7.155360 5.343670 5.343670 7.125000 7.160000 
December 2013 8.906330 7.155360 5.343670 5.343670 7.125000 7.160000 
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Month Crestor 20mg Zuvamor 20mg Vusor 20mg Storwin 20mg Rosvator 20mg 
Mediscor 
Reference Price 
January 2014 8.906330 7.155360 5.343670 5.343670 7.125000 5.350000 
February 2014 8.906330 7.155360 5.343670 5.343670 7.125000 5.350000 
March 2014 8.906330 7.155360 5.343670 5.343670 7.125000 5.350000 
April 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
May 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
June 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
July 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
August 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
September 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
October 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
November 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
December 2014 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
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Month Crestor 20mg Zuvamor 20mg Vusor 20mg Storwin 20mg Rosvator 20mg 
Mediscor 
Reference Price 
January 2015 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
February 2015 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
March 2015 9.424670 7.571790 5.654330 5.654670 5.654670 5.660000 
April 2015 10.131330 8.139640 5.654330 5.654670 6.078670 5.660000 
May 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
June 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
July 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
August 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
September 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
October 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
November 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
December 2015 10.131330 8.139640 6.075670 6.078670 6.078670 6.080000 
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APPENDIX 10 
Table 8 Candesartan utilisation, price and expenditure January 2012 to December 2015 
 
Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed per 
100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2012 465414 27973 6010.35 117091.84 4.19 0 117091.84 4.19 
February 2012 465208 29734 6391.55 125627.39 4.23 0 125627.39 4.23 
March 2012 463292 31278 6751.25 133093.88 4.26 0 133093.88 4.26 
April 2012 468478 28466 6076.27 119671.52 4.20 0 119671.52 4.20 
May 2012 460143 30264 6577.09 129342.41 4.27 0 129342.41 4.27 
June 2012 460172 27744 6029.05 118015.65 4.25 0 118015.65 4.25 
July 2012 461013 26938 5843.22 115115.04 4.27 0 115115.04 4.27 
August 2012 460341 27864 6052.90 120239.86 4.32 0 120239.86 4.32 
September 
2012 460522 24837 5393.23 106663.60 4.29 0 106663.60 4.29 
October 2012 460767 28125 6103.95 120953.97 4.30 0 120953.97 4.30 
November 
2012 460979 27168 5893.54 115546.97 4.25 0 115546.97 4.25 
December 
2012 461673 24817 5375.45 103335.72 4.16 0 103335.72 4.16 
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Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed per 
100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2013 469039 26705 5693.56 112970.82 4.23 0 112970.82 4.23 
February 2013 467804 26506 5666.05 112004.09 4.23 0 112004.09 4.23 
March 2013 467846 26524 5669.39 116516.34 4.39 0 116516.34 4.39 
April 2013 474404 25597 5395.61 114066.18 4.46 0 114066.18 4.46 
May 2013 475467 29161 6133.13 128911.23 4.42 0 128911.23 4.42 
June 2013 475451 25590 5382.26 112747.43 4.41 0 112747.43 4.41 
July 2013 476790 26391 5535.14 117178.49 4.44 0 117178.49 4.44 
August 2013 477527 27291 5715.07 119435.78 4.38 0 119435.78 4.38 
September 
2013 489698 26667 5445.60 117182.92 4.39 0 117182.92 4.39 
October 2013 489979 29236 5966.79 127128.33 4.35 0 127128.33 4.35 
November 
2013 489561 27992 5717.78 121753.86 4.35 0 121753.86 4.35 
December 
2013 490125 25366 5175.41 108679.54 4.28 0 108679.54 4.28 
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Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed per 
100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2014 495295 28243 5702.26 105908.11 3.75 0 105908.11 3.75 
February 2014 493554 26832 5436.49 88918.50 3.31 37595.92 51322.58 1.91 
March 2014 493226 28779 5834.85 91128.18 3.17 35786.78 55341.40 1.92 
April 2014 491407 24813 5049.38 76484.00 3.08 29564.33 46919.67 1.89 
May 2014 491249 25983 5289.17 78706.67 3.03 29430.66 49276.01 1.90 
June 2014 491272 24540 4995.20 74051.09 3.02 27285.80 46765.29 1.91 
July 2014 491457 25452 5178.89 78298.93 3.08 28743.99 49554.95 1.95 
August 2014 491795 26063 5299.57 77757.37 2.98 27784.00 49973.37 1.92 
September 
2014 492033 23260 4727.33 68143.17 2.93 23107.50 45035.67 1.94 
October 2014 492568 29994 6089.31 89675.23 2.99 32635.41 57039.81 1.90 
November 
2014 491848 25211 5125.77 76887.46 3.05 26885.59 50001.88 1.98 
December 
2014 492540 23590 4789.46 68958.40 2.92 23843.29 45115.10 1.91 
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Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed per 
100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2015 501949 24870 4954.69 69127.24 2.78 21361.56 47765.68 1.92 
February 2015 500695 26782 5348.96 75929.20 2.84 23459.97 52469.23 1.96 
March 2015 500030 26709 5341.48 75491.91 2.83 24291.94 51199.97 1.92 
April 2015 499210 25021 5012.12 70261.02 2.81 21437.59 48823.42 1.95 
May 2015 500567 26356 5265.23 73729.35 2.80 23100.56 50628.79 1.92 
June 2015 501548 24018 4788.77 67048.47 2.79 20424.01 46624.46 1.94 
July 2015 502770 24916 4955.75 67415.16 2.71 19499.82 47915.35 1.92 
August 2015 507329 24649 4858.58 69541.60 2.82 21627.67 47913.93 1.94 
September 
2015 502570 23061 4588.61 67736.21 2.94 21987.18 45749.03 1.98 
October 2015 501964 23143 4610.49 68553.89 2.96 22355.42 46198.47 2.00 
November 
2015 502215 21756 4332.01 65668.18 3.02 23461.58 42206.60 1.94 
December 
2015 503486 21478 4265.86 67314.48 3.13 25240.02 42074.46 1.96 
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APPENDIX 11 
Table 9 Candesartan utilisation, price and expenditure January 2012 to December 2015 
 
Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed 
per 100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-
Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2012 465414 87115.50 18717.85 684170.23 7.85 0 684170.23 7.85 
February 2012 465208 90365.50 19424.75 713375.66 7.89 0 713375.66 7.89 
March 2012 463292 95586.00 20631.91 771135.44 8.07 0 771135.44 8.07 
April 2012 468478 86729.50 18513.04 705261.33 8.13 0 705261.33 8.13 
May 2012 460143 91737.50 19936.74 744520.94 8.12 0 744520.94 8.12 
June 2012 460172 87396.50 18992.14 706724.53 8.09 0 706724.53 8.09 
July 2012 461013 86300.00 18719.65 694588.72 8.05 0 694588.72 8.05 
August 2012 460341 89669.50 19478.93 722196.26 8.05 0 722196.26 8.05 
September 2012 460522 79482.00 17259.11 643069.16 8.09 0 643069.16 8.09 
October 2012 460767 90787.50 19703.56 740948.95 8.16 0 740948.95 8.16 
November 2012 460979 85835.50 18620.26 691204.82 8.05 0 691204.82 8.05 
December 2012 461673 83412.00 18067.33 674901.01 8.09 0 674901.01 8.09 
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Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed 
per 100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-
Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2013 469039 94899.50 20232.75 760314.42 8.01 0 760314.42 8.01 
February 2013 467804 94533.50 20207.93 759806.47 8.04 0 759806.47 8.04 
March 2013 467846 94708.00 20243.41 773736.19 8.17 0 773736.19 8.17 
April 2013 474404 96039.50 20244.24 788043.44 8.21 137066.18 650977.27 6.78 
May 2013 475467 103173.50 21699.40 829620.29 8.04 137055.54 692564.74 6.71 
June 2013 475451 88400.50 18592.98 698736.60 7.90 109376.95 589359.65 6.67 
July 2013 476790 93748.50 19662.43 742237.03 7.92 163953.61 578283.42 6.17 
August 2013 477527 100521.50 21050.43 790899.39 7.87 115474.07 675425.32 6.72 
September 2013 489698 89913.00 18360.91 702092.79 7.81 97056.76 605036.03 6.73 
October 2013 489979 94665.00 19320.22 726286.37 7.67 95281.21 631005.16 6.67 
November 2013 489561 97391.00 19893.54 745261.02 7.65 97482.94 647778.08 6.65 
December 2013 490125 90051.50 18373.17 687175.11 7.63 89060.29 598114.81 6.64 
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Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed 
per 100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-
Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2014 495295 113694.00 22954.80 802628.41 7.06 229286.80 573341.61 5.04 
February 2014 493554 103632.50 20997.20 721795.59 6.96 201566.00 520229.60 5.02 
March 2014 493226 113244.00 22959.86 777815.25 6.87 213896.03 563919.22 4.98 
April 2014 491407 106326.50 21637.16 729561.85 6.86 197447.24 532114.61 5.00 
May 2014 491249 108866.50 22161.16 748878.76 6.88 197592.52 551286.24 5.06 
June 2014 491272 104519.50 21275.28 709807.96 6.79 185943.04 523864.92 5.01 
July 2014 491457 106503.00 21670.87 725705.90 6.81 186840.97 538864.93 5.06 
August 2014 491795 104463.50 21241.27 709341.14 6.79 175264.32 534076.83 5.11 
September 2014 492033 97726.50 19861.78 654833.17 6.70 161092.84 493740.33 5.05 
October 2014 492568 115080.50 23363.37 771601.36 6.70 190393.18 581208.18 5.05 
November 2014 491848 100054.50 20342.57 674058.12 6.74 163895.37 510162.76 5.10 
December 2014 492540 93712.50 19026.37 627892.22 6.70 150555.19 477337.03 5.09 
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Month 
Total 
Beneficiaries 
Total DDD 
Dispensed 
DDD 
dispensed 
per 100 000 
beneficiaries 
Total 
Monthly 
Cost 
Average 
Price per 
DDD 
Reference 
Price Co-
Pay 
Total 
Monthly 
Expenditure 
Average 
Expenditure 
per DDD 
January 2015 501949 112902.00 22492.72 729548.28 6.46 157883.87 571664.41 5.06 
February 2015 500695 117952.00 23557.65 758073.03 6.43 162712.43 595360.60 5.05 
March 2015 500030 115480.00 23094.61 745705.07 6.46 158249.30 587455.76 5.09 
April 2015 499210 113386.50 22713.19 711726.09 6.28 152492.58 559233.50 4.93 
May 2015 500567 111730.50 22320.79 716819.23 6.42 145346.92 571472.31 5.11 
June 2015 501548 103461.00 20628.33 660897.68 6.39 132690.66 528207.02 5.11 
July 2015 502770 118827.00 23634.47 747644.50 6.29 149621.99 598022.51 5.03 
August 2015 507329 110858.50 21851.40 701553.76 6.33 137585.18 563968.58 5.09 
September 2015 502570 111752.00 22236.11 706080.62 6.32 139835.33 566245.29 5.07 
October 2015 501964 107682.00 21452.14 679310.07 6.31 131744.85 547565.23 5.09 
November 2015 502215 101675.50 20245.41 647618.68 6.37 125995.00 521623.68 5.13 
December 2015 503486 97690.00 19402.72 619807.06 6.34 117920.23 501886.83 5.14 
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